NCT05672459View on ClinicalTrials.gov

A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

117

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

June 29, 2026

Study Completion Date

December 29, 2029

Conditions
Solid Tumor
Interventions
DRUG

Single Injection of IVS-3001- Anti - HLA-G CAR-T cells

Given by IV (vein)

DRUG

Fludarabine phosphate

Given by IV (vein)

DRUG

Cyclophosphamide

Given by IV (vein)

PROCEDURE

leukapheresis

Given by IV (vein)

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Invectys
All Listed Sponsors
collaborator

Invectys

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT05672459 - A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors | Biotech Hunter | Biotech Hunter